FinTechFunding

PharmAust: Continues testing COVID-19 treatment

  • PharmAust (PAA) has revealed preliminary results show its drugs are effective in inhibiting COVID-19 in human lung cells
  • Researchers in Melbourne have been testing the effect monepantel (MPL) and monepantel sulfone (MPLS) has on the deadly virus
  • This recent testing found MPL and MPLS inhibited COVID-19 in human lung cells by up to 95 per cent
  • PharmAust said following these initial results, further testing will now undertaken to better understand the drug’s effect
  • PharmAust’s Chief Scientific Officer, Richard Mollard, also said the was very pleased with these latest results
  • Shares in PAA are trading 4.26 per cent in the green at 24.5 cents each
Previous article
Perpetual Resources: Receives positive wet screening test results
Next article
Metalicity: Confirms further high-grade gold at Liepold
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...
FinTech

UK Banks Strengthen Cybersecurity with Anthropics Mythos Model

New collaboration enhances banks' defense against cyber threats.Highlights: UK banks to access Anthropics Mythos model in the upcoming...
FinTech

UK Banks to Gain Access to Anthropic Cybersecurity Model Next Week

New collaboration enhances cybersecurity for UK banking institutions.Highlights: UK banks set to access Anthropic's cybersecurity model soon.Collaboration aims...
FinTech

ABN AMRO Expands Access to Crypto Investments

The bank now offers clients direct access to cryptocurrency.Highlights: ABN AMRO now allows clients to invest in cryptocurrency...